Combining Chemoradiotherapy With Sintilimab in First-Line ICC

Not yet recruitingOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

July 1, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2028

Conditions

ICC

Interventions

RADIATION

radiotherapy

DRUG

gemcitabine + cisplatin

Gemcitabine 1000mg/m² intravenous infusion over 30 minutes, cisplatin 25mg/m² intravenous infusion, on day 1 and day 8, every 3 weeks.

DRUG

slulimumab

Slulimumab, 4.5mg/kg intravenous infusion, Q3W

Trial Locations (1)

Zhongshan Hospital, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER

NCT06447454 - Combining Chemoradiotherapy With Sintilimab in First-Line ICC | Biotech Hunter | Biotech Hunter